On 11 February 2020, the International Committee for the Classification of Viruses named the disease caused by SAＲS-CoV-2 infection in humans as the new coronavirus pneumonia (coronavirus disease 2019, COVID-19). Due to the characteristics of liver microcirculation disturbance and immune function disorder in patients with chronic liver diseases (such as immune liver disease, chronic hepatitis C, liver cirrhosis, liver cancer, etc.), those patients has a higher risk of infection than the general population during the epidemic period. More attention should be paid to personal protection and disease prevention. Vaccination of COVID-19 vaccine can effectively prevent COVID-19 virus infection and delay or prevent patients from developing into critical illness and reduce mortality. To evaluate the safety and effectiveness of COVID-19 vaccine in those patients with chronic liver diseases, and to guide the COVID-19 vaccination more scientifically, reasonably and effectively, this study was carried out.
Due to the characteristics of liver microcirculation disturbance and immune function disorder
in patients with chronic liver diseases (such as autoimmune liver disease, chronic hepatitis
C, liver cirrhosis, liver cancer, etc.), those patients has a higher risk of infection than
the general population during the epidemic period. More attention should be paid to personal
protection and disease prevention. Vaccination of COVID-19 / influenza vaccine can
effectively prevent COVID-19 / influenza virus infection and delay or prevent patients from
developing into critical illness and reduce mortality. The safety and effectiveness of
COVID-19 / influenza vaccine in this population were evaluated in order to play a scientific
and theoretical supporting role in guiding COVID-19 vaccination more scientifically,
reasonably and effectively. The samples of this study were collected and tested in the second
affiliated Hospital of Chongqing Medical University. Patients with contraindications for
vaccination will be excluded. The detected indexes included blood routine test, liver
function, COVID-19 antibody titer, antibody duration and other indexes of healthy people
(control group) and patients with chronic liver disease before and after vaccination ( 1, 3,
6, 12 months after vaccination). The adverse reactions related to the vaccine were recorded.
Biological: SARS-COV-2 VACCINE
the antibody titer and adverse reactions were observed.
Inclusion Criteria:
1. Healthy group were as follows: no history of hepatitis, no history of liver cirrhosis,
no history of liver cancer and receiving the whole-course COVID-19 vaccination.
2. Patients with chronic liver disease diagnosed clinically or pathologically and
receiving the whole-course COVID-19 vaccination.
Exclusion Criteria:
1. Patients previously diagnosed or with a history of contact with confirmed cases
2. Patients with contraindications for vaccination.
The second affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing, China
Investigator: DACHUAN CAI, PH D
Contact: 18323409779
597521685@qq.com
DACHUAN CAI, PH D
18323409779
597521685@qq.com
DAZHI ZHANG, PH D
13452382818
dzhzhang@yahoo.com
Hong Ren, PH D, Principal Investigator
The Second Affiliated Hospital of Chongqing Medical University